Jobaaj Stories
The revenue from operations of GSK Pharmaceuticals for the quarter ending in June 2022 was reported at Rs. 729.46 crores as against Rs. 791.92 crores in the last quarter of the preceding year. The revenue fell by 7.88% from the last quarter of the previous year.
The consolidated net profit for the reporting period came to Rs. 118.68 crores, whereas the reportable net profit for the previous year-same quarter came to Rs. 120.40 crores, shedding down by a negligible margin of 1.43%.
Tech Mahindra Q1 results are live and kicking! Read now.
The Earnings per share (EPS) for the quarter ending in June 2022 was Rs. 7.01, both for continuing and discontinuing operations of the company, whereas the reported EPS for the same period year-ago came to Rs. 7.11.
“Our results reflect good momentum across general medicines and vaccines during the quarter. We have delivered strong underlying growth with market share gains across focus brands. Our vaccines business has maintained leadership in the self-pay segment whereas the general vaccines market continues to be in decline. During the quarter, we have launched one of our innovative products, Trelegy Epillta, the first single inhaler triple therapy (SITT) for Chronic Obstructive Pulmonary Disease (COPD) patients in a once- daily regime for patients aged 18 and above. With this launch, we are enabling Indian COPD patients to benefit from this world leading medicine. We expect to build on this momentum as we continue to invest in our focus brands to drive growth.”, Sridhar Venkatesh, Managing Director of GSK Pharmaceuticals said in a regulatory filing.
The shares of the company fell by 2.29% to make a close at Rs.1461.45 apiece. The stock opened today at Rs 1469.1 per share.
-by Gautam
This news piece is brought to you in association with jobaaj.com
